The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Joicela | Novartis | 🇪🇺 EU | Order → | |
| Joulferon | Novartis Europharm Limited | 🇪🇺 EU | Order → | |
| Kalbitor | Dyax s.a. | 🇪🇺 EU | Order → | |
| KemSu sufentanil;ketamine | Proveca Pharma Limited | Acute Pain | 🇪🇺 EU 2026-07-23 | Order → |
| Kepnetic | Ultragenyx UK Limited | Distal Myopathies | 🇪🇺 EU | Order → |
| Ketoconazole AID-SCFM ketoconazole | Agenzia Industrie Difesa-Stabilimento Chimico Farmaceutico Militare | Cushing Syndrome | 🇪🇺 EU | Order → |
| Kiacta eprodisate disodium Orphan | Neurochem Luxco II SARL | Amyloidosis | 🇪🇺 EU | Order → |
| Kinharto omecamtiv mecarbil | Cytokinetics (Ireland) Limited | Heart Failure, Systolic | 🇪🇺 EU | Order → |
| Kinselby resminostat Orphan | 4Sc AG | Mycosis Fungoides; Sezary Syndrome | 🇪🇺 EU 2025-05-22 | Order → |
| Kizfizo temozolomide Orphan | ORPHELIA Pharma | Glioma | 🇪🇺 EU 2026-10-15 | Order → |
| Kizfizo temozolomide | ORPHELIA Pharma | Neuroblastoma | 🇪🇺 EU 2025-02-27 | Order → |
| Klygefa gefurulimab | Alexion Europe | Myasthenia Gravis | 🇪🇺 EU 2026-09-17 | Order → |
| Kynamro mipomersen sodium | Genzyme Europe BV | Hypercholesterolemia | 🇪🇺 EU 2013-03-21 | Order → |
| Kyndrisa Generic | BioMarin International Limited | Muscular Dystrophy, Duchenne | 🇪🇺 EU | Order → |
| Kyomarc bevacizumab | Amgen Europe B.V. | Carcinoma, Renal Cell; Carcinoma, Bronchogenic; Fallopian Tube Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms | 🇪🇺 EU | Order → |
| Labazenit budesonide;salmeterol | Laboratoires SMB S.A. | Asthma | 🇪🇺 EU 2013-06-27 | Order → |
| Lacosamide Pain UCB Pharma lacosamide | UCB Pharma S.A. | Diabetic Neuropathies | 🇪🇺 EU | Order → |
| Lagevrio molnupiravir | Merck Sharp & Dohme B.V. | COVID-19 virus infection | 🇪🇺 EU | Order → |
| Lenalidomide Celgene Europe lenalidomide | Celgene Europe Limited | Myelodysplastic Syndromes | 🇪🇺 EU | Order → |
| Lextemy bevacizumab Biosimilar | Mylan IRE Healthcare Limited | Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell | 🇪🇺 EU 2021-02-25 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.